2001
DOI: 10.1016/s0304-3959(01)00363-3
|View full text |Cite
|
Sign up to set email alerts
|

A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel

Abstract: Paclitaxel, an effective anti-neoplastic agent in the treatment of solid tumors, produces a dose-limiting painful peripheral neuropathy in a clinically significant number of cancer patients. Prior work has demonstrated paclitaxel-induced neurodegeneration and sensory loss in laboratory rodents. We describe here an experimental paclitaxel-induced painful peripheral neuropathy. Adult male rats were given four intraperitoneal injections on alternate days of vehicle or 0.5, 1.0, or 2.0 mg/kg of paclitaxel (Taxol).… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

25
358
2
13

Year Published

2002
2002
2017
2017

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 414 publications
(398 citation statements)
references
References 65 publications
25
358
2
13
Order By: Relevance
“…In this study, paclitaxel treatment caused mechanical allodynia/hyperalgesia and a reduction of SNCV, as previously described (Polomano et al, 2001;Persohn et al, 2005).…”
Section: Discussionmentioning
confidence: 77%
See 2 more Smart Citations
“…In this study, paclitaxel treatment caused mechanical allodynia/hyperalgesia and a reduction of SNCV, as previously described (Polomano et al, 2001;Persohn et al, 2005).…”
Section: Discussionmentioning
confidence: 77%
“…Rats were given intraperitoneal (ip) injections of paclitaxel (2 mg/kg) or vehicle (1.0 mL of Cremophor EL/dehydrated ethanol diluted in 0.9% NaCl) on 4 alternate days (days 1 [D1], 3 [D3], 5 [D5], and 7 [D7]), according to the method described by Polomano et al (Polomano et al, 2001). Body weight was recorded before and after the initiation of paclitaxel or vehicle treatment.…”
Section: Animalsmentioning
confidence: 99%
See 1 more Smart Citation
“…В експери-менті 80 рандомбредним білим щурам масою 150-200 г внутрішньоочеревинно вводили паклітак-сел (Actavis, Румунія) у дозі 2 мг/кг маси тіла через одну добу 4 рази, сумарна доза -8 мг/кг за мето-дом R.S. Polomano et al [1], після чого тварин ран-домізували на І (48 тварин) і ІІ (32 тварин) дослідні групи. У І дослідній групі тваринам вводили внутрі-шньоочеревинно 2-етил-6-метил-3-гідроксипіриди-на сукцинат (Армадін, виробництво ТОВ Науково-виробнича фірма "Мікрохім", Україна) у дозі 10 мг/кг в 0,5 мл води для ін'єкцій.…”
Section: ультраструктурні зміни в сітківці ока при корекції паклітаксunclassified
“…[37][38][39][40] Indeed, low doses of paclitaxel caused allodynia and hyperalgesia in rats without inducing degeneration of myelinated and unmyelinated axons in the sciatic nerve and roots. 41,42 Degeneration was rather confined to receptor terminals of the sensory fiber in the skin and was associated with prominent activation of cutaneous Langerhans cells. 43 The earliest defect observed in both C-fibers and myelinated axons was the appearance of swollen and vacuolated mitochondria.…”
Section: Chemotherapy-induced Peripheral Neuropathymentioning
confidence: 99%